We undertook the present analysis to examine the shifting influence of prognostic factors in HIV-positive patients diagnosed with aggressive non-Hodgkin lymphoma (NHL) over the last two decades.
the association of patient-, lymphoma-, and HIV-specific variables with the outcomes complete response (CR), progression-free survival, and overall survival (OS) in different eras: pre-cART (1989) (1990) (1991) (1992) (1993) (1994) (1995) , early cART (1996) (1997) (1998) (1999) (2000) , recent cART (2001) (2002) (2003) (2004) , and contemporary cART era (2005) (2006) (2007) (2008) (2009) (2010) .
Results: Outcomes for patients with AIDS-related diffuse large B-cell lymphoma and Burkitt lymphoma improved significantly over time, irrespective of baseline CD4 count or age-adjusted International Prognostic Index (IPI) risk category. Two-year OS was best in the contemporary era: 67% and 75% compared with 24% and 37% in the pre-cART era (P < 0.001). While the age-adjusted IPI was a significant predictor of outcome in all time periods, the influence of other factors waxed and waned. Individual HIV-related factors such as low CD4 counts (<50/mm 3 ) and prior history of AIDS were no longer associated with poor outcomes in the contemporary era.
Conclusions: Our results demonstrate a significant improvement of CR rate and survival for all patients with AIDSrelated lymphomas. Effective HIV-directed therapies reduce the impact of HIV-related prognostic factors on outcomes and allow curative antilymphoma therapy for the majority of patients with aggressive NHL. Key words: lymphoma, AIDS, HIV, diffuse large B-cell lymphoma, Burkitt lymphoma, IPI introduction The introduction of combination antiretroviral therapy (cART) in 1996 drastically altered the natural history of HIV infection and with it the management and prognosis of most patients with AIDS-related lymphoma (ARL) [1] [2] [3] [4] . Currently, five classes of antiretroviral agents are available allowing excellent viral suppression in adherent patients [5] . In addition, improved supportive care of HIV-associated morbidity has moved the management of HIV infection into the realm of a chronic disease [6] . Selected patients with ARL can now tolerate appropriately aggressive therapy and achieve outcomes similar to immunocompetent patients with de novo non-Hodgkin lymphoma (NHL) [7] [8] [9] [10] [11] [12] [13] .
In the pre-cART era, ARL outcomes were universally poor without regard to histology. Poor prognosis was associated with various patient-specific [age, i.v. drug use, performance status (PS)], HIV-specific (history of prior AIDS-defining illnesses, low CD4 count), and lymphoma-specific [stage, lactate dehydrogenase (LDH) level, extranodal disease] factors [14, 15] . Management of ARL has since evolved through different treatment eras, including evaluation of risk-adapted therapy, modifications of CHOP-based (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, the use of infusional and more doseintense regimens, the introduction and increasing utilization of rituximab in combination with chemotherapy, and improved supportive care. Outcomes improved in the early cART era, but not uniformly, notably patients with Burkitt or Burkitt-like lymphoma (BL/BLL) histology continued to have a poor prognosis [16] . At the same time, the prognostic significance of tumor-related factors [non-diffuse large B-cell lymphoma (DLBCL) histology and International Prognostic Index (IPI)] was found to be exceedingly important [17] .
In order to explore changes in prognostic factors over time on a background of the evolving management of ARL, we analyzed clinical data from over 1500 patients diagnosed with ARL within the last two decades. We previously reported how treatment-factors affected outcome in this group of patients, and our findings supported the use of rituximab, infusional regimens, and concurrent use of cART [18] . Here, we report additional analysis describing the impact of patient-, HIV-, and lymphoma-specific factors. Our objective was to determine how prognostic factors in ARL have evolved over time and to quantify their influence in the contemporary era of effective antiretroviral and lymphoma-directed therapy.
methods systematic review and data collection
We carried out a systematic review of the literature to identify prospective phase II and III clinical trials conducted in North America and Europe evaluating treatment of HIV-positive adults with newly diagnosed NHL. Details of the systematic review process, data collection, and abstraction have been previously described and can be found in supplementary Figure S1 , available at Annals of Oncology online [18] . Briefly, 42 eligible studies were identified and data were available for 19 of the 42 studies. We pooled patient-level data from each study into one dataset, checked for inconsistencies, and reanalyzed centrally. The following variables were utilized in this analysis: date of enrollment, age at enrollment, sex, histological NHL subtype (DLBCL, BL/BLL, or 'other' lymphomas), stage, LDH (normal versus elevated), number of involved extranodal sites, baseline ECOG PS, baseline CD4 count (< or ≥50 cells/mm 3 ), history of AIDS-defining events before lymphoma (h/o AIDS; absent versus present), type of chemotherapy, use of rituximab, and concurrent use of cART with chemotherapy. The study was approved by the institutional review board of Albert Einstein College of Medicine. The outcomes examined were complete response (CR) as defined by the original study protocol, progression-free survival (PFS), and overall survival (OS), defined as the time from enrollment to death from any cause (OS) or relapse or death from any cause (PFS). We calculated the age-adjusted IPI (aaIPI) based on the available information on stage, LDH, and PS. Associations of the covariates with the outcomes CR, PFS, and OS were first determined by univariate analysis and then multivariate analysis using logistic regression models for CR and Cox proportional hazard models for PFS and OS, adjusted for the other covariates, including enrollment period, type of chemotherapy, use of rituximab, and concurrent use of cART. We used separate Cox proportional hazard models adjusted for the same covariates to identify significant factors in Characteristics of the included and excluded trials have been published previously [18] . Details can be found in supplementary Appendix (Table S1 , available at Annals of Oncology online). Patient, lymphoma, HIV, and treatment characteristics for patients included in the pooled analysis are shown in Table 1 . Seventy-five percent (N = 1158) of patients were enrolled since the advent of cART, with the largest cohort enrolled during the early cART era (1996) (1997) (1998) (1999) (2000) ; N = 694). Most were male (84%) and had DLBCL (69%). There was significant heterogeneity in characteristics across the treatment eras. In the later cART eras, patients were older and were more likely to have BL/BLL, intermediatehigh or high-risk aaIPI, a prior history of AIDS, and a lower CD4 count at baseline, although the proportion of patients with CD4 <50 cells/mm 3 was stable over time (12%-17%). There was also significant heterogeneity in HIV and lymphoma-directed treatment strategies across the enrollment periods. Concurrent cART usage increased over time reaching 80% in the contemporary era. CHOP was the most common chemotherapy regimen overall, with infusional (EPOCH: etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, CDE: cyclophosphamide, doxorubicin, and etoposide) and intensive regimens investigated in more recent years. Rituximab use was sparse during the early cART era (20%) with increased utilization in the recent cART (83%) and contemporary (93%) eras.
statistical analysis

patient-and lymphoma-specific factors (histology and aaIPI) and outcomes
Multivariate analysis (adjusted for age, sex, histology, aaIPI, CD4 count, prior history of AIDS, use of cART, enrollment period, chemotherapy regimen and use of rituximab) correlating prognostic factors with treatment outcomes (CR, PFS, and OS) for all 1546 patients is shown in Table 2 . Neither age nor sex was associated with any outcome. BL/BLL histology compared with DLBCL was associated in both uni-and multivariate analysis with a reduced CR rate [OR 0.71; 95% confidence interval (CI) 0.48-1.07; P = 0.10], shortened PFS [hazard ratio (HR) 1.36; 95% CI 1.06-1.75; P = 0.02] and OS (HR 1.18; 95% CI 0.94-1.47; P = 0.16), although this was only statistically significant for PFS. In addition, in multivariate analysis, histology other than DLBCL or BL/BLL was associated with lack of CR (OR 0.39; 95% CI 0.15-0.99; P = 0.047) and worse PFS (HR 1.61; 95% CI 0.93-2.62) and OS (HR 1.17; 95% CI 0.71-1.83), although the association was not statistically significant for survival outcomes. In contrast, in both univariate and multivariate models, each 1-point increase in aaIPI (range 0-3) was strongly associated with inferior clinical outcomes (P < 0.001 for all measures): CR (OR 0.48; 95% CI 0.40-0.58), PFS (HR 1.58; 95% CI 1.40-1.80), and OS (HR 1.52; 95% CI 1.37-1.69).
HIV-specific factors ( prior AIDS and CD4 <50) and outcomes
Factors correlating with advanced HIV infection were also associated with significantly inferior clinical outcomes. In univariate analysis, an AIDS-defining illness before lymphoma was associated with lack of CR and worse OS, but not with PFS. These associations remained significant in multivariate analysis (OR for CR: 0.66; 95% CI 0.45-0.96; P = 0.031, and HR for OS: 1.25, 95% CI 1.01-1.53; P = 0.036). Similarly, patients with baseline CD4 <50 cells/mm 3 had inferior CR rates (OR 0.42; 95% CI 0.26-0.67; P < 0.001) and OS (HR for CD4 <50: 1.78; 95% CI 1.38-2.27; P < 0.001) in both univariate and multivariate analysis. In univariate analysis, CD4 <50 cells/mm 3 was also associated with inferior PFS (HR 1.37, 95% CI 1.08-1.70; P = 0.006) but not significantly after multivariate adjustment (P = 0.09).
treatment eras and outcomes
We then compared treatment outcomes both between pre-cART and cART era as well as within the cART era (early, recent, contemporary). Treatment outcomes (CR, PFS, and OS) significantly improved both for patients with DLBCL and BL/BLL throughout successive treatment eras since the introduction of cART (Table 3 and supplementary Table S2 , available at Annals of Oncology online; Figure 1A and B). Compared with the precART era patients with DBCL in the cART era had improved CR (47%-61%), 2-year PFS (43%-65%), and 2-year OS (24%-57%), with the most substantive gains in the contemporary era (CR 65%, 2-year PFS 76%, 2-year OS 67%). The corresponding gain in CR rates for patients with BL/BLL in the cART era was less pronounced (56% pre-cART to 59% cART) but reached 78% in the contemporary era. Patients with BL/BLL also had improvements in 2-year PFS (46%-56%) and 2-year OS (37%-55%). Whereas substantial survival gains were first observed for patients with DLBCL in the recent era, they were delayed for patients with BL/BLL until the contemporary era. Treatment outcomes also improved for patients with CD4 counts <50 (except PFS) and ≥50 cells/mm 3 in the cART era ( Figure 1C and D) and for patients with all aaIPI risk groups (except for CR in patients with low-risk aaIPI; see supplementary Table S2 and Figure S2 , available at Annals of Oncology online). Improvement in survival was most substantial for patients with CD4 <50 cells/mm 3 enrolled in the contemporary era when the 2-year OS rate reached 65% from only 16% in the pre-cART era. The best outcomes were seen among patients with low (aaIPI = 0) aaIPI in the contemporary era when 2-year OS was 100%. Although CR rates also improved for high-risk (aaIPI = 3) patients from pre-cART into the contemporary era (25%-51%), survival remained poor (median OS 1.01 years; 2-year OS 49%). See supplementary Table S2 , available at Annals of Oncology online, for results on CR rate and PFS within the cART eras and supplementary Figure S2 , available at Annals of Oncology online, which provides KM curves according to aaIPI risk groups. The significant prognostic factors identified in Table 2 (histological subtype, aaIPI, prior history of AIDS and CD4 <50) pertain to the entire cohort of 1546 patients analyzed 'en masse' throughout the study period. Given substantial improvements in outcomes observed over time, we then sought to determine whether the relevance of prognostic factors was influenced by enrollment period even within the cART era. Table 4 Annals of Oncology era (HR 2.11; 95% CI 1.22-3.67; P = 0.008). Also not previously identified as a significant prognostic factor, increasing age was associated with worse OS in the pre-cART (HR 1.02; 95% CI 1.01-1.04; P < 0.01) and again in the contemporary era (HR 1.05; 95% CI 1.00-1.10; P = 0.035).
The prognostic significance of HIV-specific factors was limited to the early and recent cART eras. Thus, baseline CD4 <50 cells/mm 3 was associated with worse OS during early and recent cART but was not significant in neither pre-cART nor contemporary era. Similarly, a prior history of AIDS increased the risk of death only in the early cART era and with borderline significance during recent cART. In contrast, the aaIPI was significantly associated with inferior survival in each treatment era, with the greatest magnitude in the contemporary era (HR 2.34; 95% CI 1.54-3.56; P < 0.0001). There was no significant interaction between each prognostic factor and enrollment.
discussion
This pooled analysis of patient-level data from 1546 patients with ARL examined outcomes and prognostic factors over 20 years that span pre-cART and cART eras and evolving HIVand lymphoma-directed therapies. We found significant and continually improving outcomes for patients with ARL through the cART eras, including those with DLBCL and BL/BLL subtypes, irrespective of CD4 count or aaIPI. As previously described by others [14, 17] , the significance of important prognostic factors changed over time with the IPI being the only consistent prognostic factor in all time periods.
We also noted significant shifts in patient characteristics of our cohort over time, the most striking of which is an inversion of the histological distribution of lymphomas enrolled into trials: while DLBCL was the most common diagnosis in the pre-cART era (73%), more patients in our cohort were diagnosed with BL/ BLL in the contemporary era (55%). While this redistribution could represent a selection bias in our cohort, the observation is supported by other studies. In the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) study, which examined a large general population cohort of HIV-infected patients in the cART era stratified by the same three time periods, a proportional increase in BL was found [19] . Similarly, the HIV/AIDS Cancer Match Study described a decreased incidence of HIV-associated DLBCL and PCNSL but not BL [20] .
In general, our findings confirm earlier analyses showing improved outcomes for patients with DLBCL in the cART era and further support extension of these gains for patients with BL/BLL, but only in the contemporary era. Earlier studies described improved survival in the cART era for patients with DLBCL but not for BL/BLL [16, 21] . Such initial failure for BL outcomes to keep pace with DLBCL after cART can likely be attributed to the ineffectiveness of early treatment strategies, especially the use of less intensive CHOP-based regimens [22] . Our findings support more recent evidence showing feasibility and improved outcomes for BL treated with dose-intensive strategies or infusional regimens [10, 11, 23, 24] . In contrast, the CNICS study found ARL mortality to be static across the cART era, and to be inferior to what is expected for HIV-uninfected patients [19] . Whereas our study included only patients enrolled on clinical trials, the poorer outcomes in the CNICS cohort are likely multifactorial: selection bias in our own cohort; the lag time between clinical trial findings and changes to standard of care; and the impact on survival of access to care and various other unaccounted social factors [25] . Nevertheless, our results likely reflect increased utilization of intensive and/or infusional regimens, and of rituximab, which reached 93% in the contemporary era, as well as improved HIV control and supportive care. Interpretation of the results for patients with histologies other than DLBCL or BL/BLL in our analysis is limited by the lack of available information on the exact histological subtypes.
In keeping with improved outcomes and the evolving treatment paradigm of ARL, we found a modification of significant prognostic factors over time. As outcomes improved, tumorrelated factors became increasingly important. In our study, the aaIPI is the most important and consistent prognostic factor in Table 3 . Two-year overall survival according to enrollment period 2-year overall survival (%, 95% CI) Pre-cART (1990) (1991) (1992) (1993) (1994) (1995) patients with ARL with increasing value in the contemporary era. While the validity of the IPI in risk-stratification of patients with ARL has been consistently demonstrated [14, 17, [26] [27] [28] , there have been variable findings on the relevance of HIVspecific factors, with some demonstrating less importance over time [14, 27] and others failing to demonstrate any prognostic relevance at all [17] . We found that while HIV-specific factors ( prior AIDS and CD4 <50 cells/mm 3 ) were associated with poor prognosis in the whole-group analysis, their relevance waxed and waned. HIV-related factors appeared to have less impact on survival in the pre-cART era, when outcomes were universally poor and determined by the inability to deliver effective lymphoma care. The same was observed again in the contemporary era; the most likely explanation for this finding is the high efficiency of contemporary HIV-directed care that enables excellent HIV control for most patients and results in the relative loss of prognostic importance of a single-individual HIVrelated factor. Similarly, the relative shift of prognostic influence of histology on outcome in ARL is most likely a reflection of the shifts in lymphoma-directed care over the different eras.
Limitations of our analysis may affect the generalizability of some findings. Selection bias is inherent in clinical trial enrollment and thus the analyzed patient population may not reflect the general population of HIV-infected patients with NHL. Also, unexpectedly high CD4 counts observed in the pre-cART era may further reflect selection bias during that era. Additional bias may arise from our failure to obtain data from all eligible trials, although the majority of these were conducted in the precART era and were of small sample size. While we used patientlevel data and were able to control for many confounders, we relied on investigator reports of classifications of response, relapse, and histology. This particularly limits the utility of the outcomes CR and PFS, but should not affect the estimates for OS as this is a variable independent of investigator bias. In addition, missing data may have led to imprecise estimates, and although we adjusted for known variables, other unknown factors over the 20-year time frame may confound results.
On the other hand, several factors strengthen the robustness of this analysis. Previous reports on outcomes and prognostic factors in the cART era were limited by sample size, retrospective analysis, and shorter timeframes. This analysis is the largest and most comprehensive to date, including the majority of patients enrolled on clinical trials of ARL in the cART era at major centers in the United States and Europe, and the first such analysis to include patients treated in the contemporary era. We were able to adjust estimates for all known prognostic factors and important confounding variables, especially treatment, the use of rituximab and enrollment period. The large sample size also allowed subgroup analysis to reveal subtle trends in outcomes and prognostic factors over time.
In conclusion, outcomes have improved dramatically for all patients with ARL, despite a lag in benefit for patients with BL/ BLL histology. The importance of HIV-related factors has waned over time and for the two most common subtypes (DLBCL and BL), histology may no longer be an important prognostic factor with current histology-directed treatment approaches. Thus, the aaIPI prevailed as the only consistent prognostic factor. As evidenced by the survival rates, we observed in the contemporary era, cure for HIV-positive patients with NHL can be achieved similarly to immunocompetent patients when adequate antiviral and histology-directed antilymphoma therapy is being utilized. Given this, patients with lymphoma should no longer be excluded from participation in lymphoma clinical trials solely based on their HIV status. 
